Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Jul 1;30(7):551-64.
doi: 10.2165/11590120-000000000-00000.

Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models

Affiliations
Meta-Analysis

Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models

Kristian Bolin. Pharmacoeconomics. .

Abstract

Background: Smoking is probably the most important among preventable health risks. Health economic evaluation of smoking-cessation interventions, applying a lifetime perspective, is made possible by available epidemiological knowledge. The well established method of performing cost-effectiveness analyses of smoking-cessation interventions involves mathematical modelling (both deterministic and stochastic) of future events important for cost effectiveness.

Objectives: This study surveys cost-effectiveness analyses of smoking cessation, with a particular focus on the mathematical modelling and simulation analyses performed.

Data sources: A systematic literature search was performed using the databases MEDLINE, Econlit and Academic Search Complete.

Study selection: Health economic evaluations, published as full-length journal articles, were searched for.

Results: 423 studies were identified and 78 were finally included, of which 30 were assessed as being highly relevant, based on the application of simulation modelling.

Conclusions: In general, studies are well performed as regards modelling. Common weaknesses include reporting of modelling details; validation of used simulation models; and the handling of structural uncertainty and different types of heterogeneity.

PubMed Disclaimer

References

    1. Clin Drug Investig. 2009;29(10):655-65 - PubMed
    1. Curr Med Res Opin. 2010 Mar;26(3):549-60 - PubMed
    1. J Policy Anal Manage. 2004 Aug;23(4):857-72 - PubMed
    1. Math Med Biol. 2010 Mar;27(1):1-19 - PubMed
    1. Tob Control. 2006 Jun;15(3):152-9 - PubMed

LinkOut - more resources